Weidmann, Chase A. http://orcid.org/0000-0002-2941-0500
Mustoe, Anthony M.
Jariwala, Parth B.
Calabrese, J. Mauro
Weeks, Kevin M. http://orcid.org/0000-0002-6748-9985
Funding for this research was provided by:
American Cancer Society (130845-RSG-17-114-01-RMC)
U.S. Department of Health & Human Services | National Institutes of Health (R01 GM121806, R35 GM122532)
National Science Foundation (MCB-1121024)
Article History
Received: 4 January 2020
Accepted: 16 September 2020
First Online: 19 October 2020
Competing interests
: A.M.M. is an advisor to and K.M.W. is an advisor to and holds equity in Ribometrix, to which mutational profiling technologies have been licensed.